Investors

IR Overview

IR Overview

From SITC, Samik Basu talks about our recent ADP-A2M4 translational data

IR OVERVIEW

Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patient’s own T-cells to express our SPEAR TCRs to target and potentially destroy tumors.

Our wholly-owned pipeline includes SPEAR T-cell therapies targeting ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4), and ADP-A2AFP (AFP), which are being investigated in clinical studies across multiple solid tumor indications. We continue to build a pipeline of further proprietary TCR therapeutic candidates, second generation treatment options, as well as allogeneic (off-the-shelf) solutions.

We believe our approach will lead to SPEAR T-cells with the potential to significantly impact cancer treatment and the clinical outcomes of cancer patients.

 

Recent News

More >>
Date Title  
Toggle Summary Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma
- Clinical responses in seven out of 14 patients with synovial sarcoma by RECIST 1.1 - - Clinical benefit in 13 out of 14 patients - - One RECIST response maintained for more than 9 months after SPEAR T-cell infusion - PHILADELPHIA and OXFORDSHIRE, United Kingdom , Nov.
Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma
- Clinical responses in seven out of 14 patients with synovial sarcoma by RECIST 1.1 - - Clinical benefit in 13 out of 14 patients - - One RECIST response maintained for more than 9 months after SPEAR T-cell infusion - PHILADELPHIA and OXFORDSHIRE, United Kingdom , Nov.
Toggle Summary Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update
- Clinical responses with ADP-A2M4 in 7 out of 12 patients with synovial sarcoma, and clinical benefit in 11 out of 12 patients - - ADP-A2M4 granted Orphan Drug Designation for treatment of soft tissue sarcomas - - Enrolling across SPEARHEAD-1 and SURPASS trials at multiple sites - - Progress
Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update
- Clinical responses with ADP-A2M4 in 7 out of 12 patients with synovial sarcoma, and clinical benefit in 11 out of 12 patients - - ADP-A2M4 granted Orphan Drug Designation for treatment of soft tissue sarcomas - - Enrolling across SPEARHEAD-1 and SURPASS trials at multiple sites - - Progress
Toggle Summary Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019
PHILADELPHIA and OXFORDSHIRE, United Kingdom , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Third Quarter 2019 and provide a business update, before the U.S.
Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019
PHILADELPHIA and OXFORDSHIRE, United Kingdom , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Third Quarter 2019 and provide a business update, before the U.S.
Toggle Summary Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies
Key step toward commercial-readiness for ADP-A2M4 therapy with launch planned for 2022   PHILADELPHIA and OXFORDSHIRE, United Kingdom and IRVINE, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Cryoport, Inc.
Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies
Key step toward commercial-readiness for ADP-A2M4 therapy with launch planned for 2022   PHILADELPHIA and OXFORDSHIRE, United Kingdom and IRVINE, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Cryoport, Inc.

Copyright West LLC. Minimum 15 minutes delayed.

Upcoming Events

More >>
There are currently no events to display.

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just click here.